Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Takeda Pharmaceutical Company Limited American Depositary Shares (each
(NY:
TAK
)
16.96
+0.24 (+1.44%)
Streaming Delayed Price
Updated: 11:50 AM EDT, Aug 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each
< Previous
1
2
...
8
9
10
11
12
13
14
15
16
...
20
21
Next >
Gamma Delta T Cell Therapy Market Could Reach $4 Billion As Biotechs Race To Get Breakthrough Cancer Treatment Approved
↗
November 22, 2022
This year, the World Health Organization (WHO) announced that cancer has become the leading cause of death worldwide, with the latest data showing that nearly 10 million deaths in 2020 were the result...
Via
Benzinga
Why Puma Biotechnology's Shares Jumped 20% on Monday
↗
November 21, 2022
It may have benefited from positive news about another company's drug candidate.
Via
The Motley Fool
Takeda's Approved Blood Cancer Drug Hits Primary Goal In Newly-Diagnosed Patient Settings
↗
November 17, 2022
Via
Benzinga
Phase 3 Trial of ICLUSIG® (ponatinib) Met Primary Endpoint in Newly-Diagnosed Ph+ ALL, a Setting with No Targeted Treatments Approved in the US
November 17, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Posts Lower 1H Profit, Lifts FY22 Outlook
↗
October 27, 2022
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
↗
October 19, 2022
On Wednesday, 200 companies hit new 52-week lows.
Via
Benzinga
Takeda Seeks FDA Approval For Hereditary Angioedema Treatment For Younger Kids
↗
October 05, 2022
Via
Benzinga
2 Beaten-Down Dividend Stocks That Haven't Been This Cheap In More Than a Decade
↗
November 16, 2022
Is now the time to load up on these high-yielding investments?
Via
The Motley Fool
European Commission (EC) Approves LIVTENCITYTM▼ (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Infection And/or Disease That Are Refractory (With or Without Resistance) to One or More Prior Therapies
November 11, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Why Denali Therapeutics' Stock Rose 6.6% on Wednesday
↗
November 02, 2022
The biopharmaceutical stock was actually up as much as 12.4% before falling a bit at the close.
Via
The Motley Fool
Takeda Delivers Strong FY2022 H1 Results and Raises Full-Year Forecast
October 27, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Earnings Scheduled For October 27, 2022
↗
October 27, 2022
Companies Reporting Before The Bell • Janus Henderson Gr (NYSE:JHG) is expected to report quarterly earnings at $0.48 per share on revenue of $494.27 million.
Via
Benzinga
7 Dividend Stocks to Sell Pronto Before a Painful Downturn
↗
October 24, 2022
Investors may find many dividend stocks to sell, considering returns from the risk-free U.S. Treasury Bills often exceed their yield.
Via
InvestorPlace
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
↗
October 20, 2022
Despite enthusiasm in some camps, the risk of potential cures clouds market projections.
Via
Investor's Business Daily
Takeda Enters Collaboration and Licensing Agreement with Zedira and Dr. Falk Pharma to Develop First-in-Class Celiac Disease Therapy
October 20, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
3 High-Yielding Dividend Stocks Near Their 52-Week Lows
↗
October 19, 2022
These stocks all pay far higher than the S&P 500 average dividend yield of 1.8%.
Via
The Motley Fool
Takeda Receives Positive CHMP Opinion Recommending Approval of Dengue Vaccine Candidate in EU and Dengue-Endemic Countries
October 14, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Scientists Are Studying Psychedelic Drug as a Possible Treatment for Alzheimer’s Disease
October 05, 2022
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – October 5, 2022 – A Toronto-based biotech firm is developing a new psychedelic medicine to cure Alzheimer’s disease,...
Via
FinancialNewsMedia
Topics
Cannabis
U.S. Food and Drug Administration Accepts Takeda’s Supplemental Biologics License Application for Use of TAKHZYRO® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older
October 05, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Strengthening Healthcare Systems to Meet Patients’ Need for Plasma-Derived Therapies
September 29, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
↗
September 21, 2022
Via
Benzinga
Takeda Signs Virtual Power Purchase Agreement with Enel North America to Advance Renewable Energy Production in the United States
September 19, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Receives Positive CHMP Opinion for Maribavir for the Treatment of Adults with Post-transplant Cytomegalovirus (CMV) Refractory (With or Without Resistance) to Prior Therapies
September 16, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Intellia Therapeutics Looks To Repeat Its Landmark Success In CRISPR Gene Editing
↗
September 16, 2022
Intellia tested its CRISPR approach in cardiomyopathy and hereditary angioedema.
Via
Investor's Business Daily
Takeda Selects New Partners for Global Corporate Social Responsibility (CSR) Program to Strengthen Health Systems in Low- and Middle-Income Countries
September 13, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
7 Stocks Under $15 to Buy and Hold Forever
↗
September 01, 2022
For patient investors who are willing to absorb potential turbulence, these are the stocks under $15 to buy for the long haul.
Via
InvestorPlace
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
↗
August 30, 2022
Via
Benzinga
Y-mAbs Gets Regulatory Approval In Israel For Neuroblastoma Candidate
↗
August 30, 2022
The Israeli Ministry of Health has approved Y-mAbs Therapeutics’ (NASDAQ: YMAB) lead drug DANYELZA in combination with granulocyte-macrophage colony-stimulating factor for pediatric patients 1 year of...
Via
Benzinga
With Approval For Dengue Vaccine, Takeda May Find It Challenging To Compete Bigger Rivals: Report
↗
August 30, 2022
Via
Benzinga
Benzinga Before The Bell: Elon Musk's Demand For Broad Twitter Data Dismissed, Xiaomi Wants To Join EV Race, Bed Bath & Beyond Plans To Share Turnaround Strategy Next Week And Other Top Financial Stories Friday, August 26
↗
August 26, 2022
CNBC The Aviation Sector Is Slammed By Sky-High Rents
Via
Benzinga
< Previous
1
2
...
8
9
10
11
12
13
14
15
16
...
20
21
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
